David H Kirn

David H Kirn

UNVERIFIED PROFILE

Are you David H Kirn?   Register this Author

Register author
David H Kirn

David H Kirn

Publications by authors named "David H Kirn"

Are you David H Kirn?   Register this Author

44Publications

622Reads

-Profile Views

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Cancer Res 2018 02 19;78(4):922-937. Epub 2017 Dec 19.

UCSF Helen Diller Family Comprehensive Cancer Center, Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-3308DOI Listing
February 2018

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Curr Opin Virol 2015 Aug 17;13:49-54. Epub 2015 Apr 17.

SillaJen Biotherapeutics, 450 Sansome St, Suite 650, San Francisco, CA 94111, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coviro.2015.03.016DOI Listing
August 2015

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Sci Transl Med 2013 May;5(185):185ra63

Pusan National University and Medical Research Institute, Pusan National University, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3005361DOI Listing
May 2013

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Curr Pharm Biotechnol 2012 Jul;13(9):1768-72

Jennerex Inc. San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://cc.bjmu.edu.cn/download/8b61e65c6fa14541b79de5432022-
Web Search
July 2012

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):135-41. Epub 2010 Mar 24.

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S135961011000018
Publisher Site
http://dx.doi.org/10.1016/j.cytogfr.2010.02.007DOI Listing
September 2010

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):85-9. Epub 2010 May 15.

Jennerex Inc., San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cytogfr.2010.02.001DOI Listing
September 2010

Oncolytic virotherapy for advanced liver tumours.

J Cell Mol Med 2009 Jul 23;13(7):1238-47. Epub 2008 Oct 23.

Department of Pathology and Immunology, Washington University in Saint Louis, Saint Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1582-4934.2008.00563.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496138PMC
July 2009

Targeted genetic and viral therapy for advanced head and neck cancers.

Drug Discov Today 2009 Jun 17;14(11-12):570-8. Epub 2009 Mar 17.

Cancer Center, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S135964460900084
Publisher Site
http://dx.doi.org/10.1016/j.drudis.2009.03.008DOI Listing
June 2009

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Nat Rev Cancer 2009 Jan;9(1):64-71

Jennerex Biotherapeutics Inc., San Francisco, California 94105, USA .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2545
Publisher Site
http://dx.doi.org/10.1038/nrc2545DOI Listing
January 2009

Development of targeted oncolytic virotherapeutics through translational research.

Expert Opin Biol Ther 2008 Sep;8(9):1381-91

Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.8.9.1381 DOI Listing
September 2008

Oncolytic adenoviruses for cancer gene therapy.

Methods Mol Biol 2008 ;433:243-58

Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-59745-237-3_15
Publisher Site
http://dx.doi.org/10.1007/978-1-59745-237-3_15DOI Listing
August 2008

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Cancer Res 2008 Apr;68(7):2071-5

Jennerex Biotherapeutics, Ltd., San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-6515DOI Listing
April 2008

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

PLoS Med 2007 Dec;4(12):e353

Jennerex Biotherapeutics, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.0040353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222946PMC
December 2007

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

Curr Cancer Drug Targets 2007 Mar;7(2):133-9

JENNEREX Biotherapeutics, San Francisco, CA 94105, USA.

View Article

Download full-text PDF

Source
March 2007

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

Mol Ther 2006 May 8;13(5):938-46. Epub 2006 Feb 8.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2005.12.010DOI Listing
May 2006

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Curr Gene Ther 2005 Aug;5(4):429-43

JENNEREX Biotherapeutics, Mill Valley, CA, USA.

View Article

Download full-text PDF

Source
August 2005

Vaccinia virus and oncolytic virotherapy of cancer.

Curr Opin Mol Ther 2005 Aug;7(4):359-65

Stanford University School of Medicine, Department of Pediatrics and Bio-X Program, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
August 2005

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.

Expert Opin Biol Ther 2004 Aug;4(8):1307-21

Bio-X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.4.8.1307 DOI Listing
August 2004

Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

Int J Oncol 2004 Jul;25(1):173-8

Molecular Oncology Unit, Cancer Research UK, Imperial College London Hammersmith Hospital, London W12 0NN, UK.

View Article

Download full-text PDF

Source
July 2004

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response.

Bull Math Biol 2004 Jul;66(4):605-25

School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulm.2003.08.016DOI Listing
July 2004

Replication-selective oncolytic adenoviruses.

Methods Mol Med 2004 ;90:71-90

Viral and Genetic Therapy Programme, Cancer Research UK and Imperial College School of Medicine, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
March 2004

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.

Cancer Res 2003 Mar;63(6):1317-24

Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
March 2003

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Clin Cancer Res 2003 Feb;9(2):555-61

Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
February 2003

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.

Surg Oncol Clin N Am 2002 Jul;11(3):571-88, vi

Department of Surgery, University of California-San Francisco, 533 Parnassus Avenue, U-372, San Francisco, CA 94143-0790, USA.

View Article

Download full-text PDF

Source
July 2002

Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

Cancer Res 2002 Feb;62(3):764-72

Department of Pediatrics, Laboratory of Pharmacotoxicology, Institut Gustave-Roussy, 39 Rue Camille Desmoulins, 94 805 Villejuif, France.

View Article

Download full-text PDF

Source
February 2002